In this study, a magnetic core–shell metal–organic
framework (MOF) nanocomposite, Fe3O4-COOH@UiO-66-NH2, was synthesized for tumor-targeting drug delivery by incorporating
carboxylate groups as functional groups onto ferrite nanoparticle
surfaces, followed by fabrication of the UiO-66-NH2 shell
using a facile self-assembly approach. The anticancer drug quercetin
(QU) was loaded into the magnetic core–shell nanoparticles.
The synthesized magnetic nanoparticles were comprehensively evaluated
through multiple techniques, including FT-IR, PXRD, FE-SEM, TEM, EDX,
BET, UV–vis, ZP, and VSM. Drug release investigations were
conducted to investigate the release behavior of QU from the nanocomposite
at two different pH values (7.4 and 5.4). The results revealed that
QU@Fe3O4-COOH@UiO-66-NH2 exhibited
a high loading capacity of 43.1% and pH-dependent release behavior,
maintaining sustained release characteristics over a prolonged duration
of 11 days. Furthermore, cytotoxicity assays using the human breast
cancer cell line MDA-MB-231 and the normal cell line HEK-293 were
performed to evaluate the cytotoxic effects of QU, UiO-66-NH2, Fe3O4-COOH, Fe3O4-COOH@UiO-66-NH2, and QU@Fe3O4-COOH@UiO-66-NH2. Treatment with QU@Fe3O4-COOH@UiO-66-NH2 substantially reduced the cell viability in cancerous MDA-MB-231
cells. Cellular uptake and cell death mechanisms were further investigated,
demonstrating the internalization of QU@Fe3O4-COOH@UiO-66-NH2 by cancer cells and the induction of
cancer cell death through the apoptosis pathway. These findings highlight
the considerable potential of Fe3O4-COOH@UiO-66-NH2 as a targeted nanocarrier for the delivery of anticancer
drugs